GSK Launches Iodex UltraGel

The clinically proven formulation provides three times effective pain relief 
Strengthens GSK’s presence in the topical pain relief segment.
by Shrutee K/DNS
New Delhi : GSK announced the launch of Iodex UltraGel, a new age clinically proven gel-based body pain solution. Backed by science, the new variant penetrates to the root cause of pain, reduces internal swelling and gives 3X effective relief. ^ With this launch, GSK strengthens its presence in the topical pain relief category.
While ordinary counter-irritant pain relief creams give burning sensation on the skin, the new Iodex UltraGel with emulgel formulation contains Diclofenac Diethylamine 1.16% w/w, that penetrates deep to the source of pain to give effective relief. The product has modern sensorials like pleasant smell, non-greasy texture and cooling sensation which makes it a convenient pain relief solution both at home and on the go.
The launch strengthens GSK’s pain relief portfolio in India making it one of the formidable players in the non-prescription space. GSK is a global leader in pain management (OTC).*
Iodex UltraGel was exclusively previewed at the Indian Orthopaedic Association Annual Conference’19  (IOACON), one of the biggest orthopaedic conglomerations in South Asia. As part of the launch, the brand will be reaching out to over 5000 orthopaedics to promote the clinically proven credentials of the new product. 
Naveed Ahmed, Area Marketing Director, GSK said, “Brand Iodex has stayed relevant for over a century making it a household name that is trusted by millions. Today’s changing lifestyle has resulted in an increase in pain occurrences, be it back, neck & shoulder or joint pains.  We are addressing the needs of these sets of consumers by launching Iodex UltraGel, a clinically proven formulation that will offer effective pain relief, making it one of the best pain solutions available in the market. We are confident that this launch will further augment consumer trust in the brand and help strengthen our topical pain relief portfolio.”
Iodex is one of India's leading topical pain relievers. It was launched 100 years ago and has since become a household brand, selling over 4 million bottles every month. Iodex UltraGel is available in two packs- 15 g at Rs. 65 and 30 g at Rs. 125 and is available across all leading chemist stores pan-India.
About GlaxoSmithKline Consumer Healthcare Ltd: GSK Consumer Healthcare Ltd (GSKCH) is one of the category leaders in Indian health food drinks industry. Our flagship product Horlicks leads the market, while Boost is among the top three health food drink brands that India prefers. Our manufacturing plants are located in Nabha, Rajahmundry and Sonepat. In India, we have an engaged workforce of over 4700 employees. GSKCH also markets and distributes a range of everyday health products such as Eno, Crocin, Iodex and Sensodyne. Our marketing and distribution network comprises over 700 distributors and a direct coverage of over 8 lakh retail outlets.
GSK Consumer Healthcare Ltd is an associate of GlaxoSmithKline plc. of U.K, one of world’s largest consumer healthcare companies. We have a heritage that goes back over 160 years. Our purpose is to help more people around the world to do more, feel better and live longer with everyday healthcare products.  Our goal is to build a global, growing business - we call a Fast Moving Consumer Healthcare (FMCH) company - dedicated to everyday healthcare with all of the scientific expertise and quality guarantees that demands, working at the speed and with the genuine consumer understanding the modern world expects. GSK group of companies globally owns some of the world’s best loved healthcare brands, successful in over 100 countries. These include Sensodyne, Voltaren, Theraflu, Paradontax, Panadol, Polident, Otrivin, Horlicks and Physiogel.

Comments

Popular posts from this blog

7th Edition of Children Baby Maternity Expo India

Club Factory Kicks off Diwali Flash Sale from September 29 – October 2

Gulzar gets Indira Gandhi National Integration Award-